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Abstract 
 
The present review discusses the potential role of neurosteroids / neuroactive steroids in 
the regulation of nociceptive and neuropathic pain, and recapitulates the current 
knowledge on the main mechanisms involved in the reduction of pain, especially those 
occurring at the dorsal horn of the spinal cord, a crucial site for nociceptive processing. We 
will make special focus on progesterone and its derivative allopregnanolone, which have 
been shown to exert remarkable actions in order to prevent or reverse the maladaptive 
changes and pain behaviors that arise after nervous system damage in various 
experimental neuropathic conditions. 
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1. Introduction 
Almost 35 years have gone by since the pioneering works of Baulieu and colleagues 
showed that the rat nervous system is capable of synthesizing bioactive steroids [1,2]. This 
discovery gave birth to the term “neurosteroids”, e.g. steroids produced by the nervous 
system [3], while “neuroactive steroids” refers to steroids acting in the nervous system by 
modulating inhibitory or excitatory neurotransmitter receptors and neuronal excitability [4]. 
However, this notion has been extended to all steroids that directly act on neurons, either 
via membrane or nuclear signaling mechanisms [5], and includes those synthesized locally 
and in the peripheral glands (ovary, testis and adrenal glands) and also synthetic steroids 
[6].  
Among these molecules, progesterone and its derivative allopregnanolone (ALLO) exert a 
wide range of fascinating actions in the central nervous system. In fact, an impressive 
number of pharmacological and behavioral studies have demonstrated that these 
neurosteroids /neuroactive steroids are involved in the control of several and diverse 
biological mechanisms such as cognition, stress, anxiety, depression, neuroprotection and 
myelination, which have been extensively reviewed elsewhere [6-12]. Furthermore, an 
important area of research has been devoted to explore the role of these steroids and 
related molecules in the modulation of both nociceptive [13-16] and neuropathic [17-30] 
pain, providing clear evidences towards the development of steroid-based therapies to 
counteract chronic pain conditions. 
The present review discusses the potential role of neuroactive steroids in the regulation of 
nociceptive and neuropathic pain, and recapitulates the current knowledge on the main 
mechanisms involved, making reference mainly to those occurring at the spinal cord, a 
crucial site for nociceptive processing. We will make special focus on progesterone and 
ALLO, which have been shown to exert remarkable actions tending to prevent or reverse 
the maladaptive changes and pain behaviors that arise after nervous system damage in 
various experimental neuropathic conditions. 
2. Steroids and nociceptive pain  
Nociceptive pain represents a pivotal defensive mechanism intended to warn an individual 
of recent, ongoing or imminent damage to the body. In this context, the ability to detect 
noxious stimuli is essential to an organism’s survival and wellbeing [31,32]. Mechanical, 
thermal and chemical noxious stimuli are detected by a subpopulation of primary afferent 
neurons called nociceptors [31,33]. Nociceptors have cell bodies located in dorsal root 
ganglia, a peripheral axonal branch that innervates tissues and organs, and a central 
branch that synapse on second order neurons, and local interneurons, within the dorsal 
horn of the spinal cord [31,33] (Fig 1). Some second order neurons act as projection 
neurons and convey nociceptive information to the somatosensory cortex, via several 
brainstem and thalamic nuclei [31,34]. Supraspinal control of nociceptive signaling is 
relayed through the midbrain periaqueductal gray matter, the serotoninergic raphe 
nucleus, the noradrenergic locus coeruleus and the rostral ventromedial medulla, that 
directly or indirectly project to the dorsal horn [35,36]  
  
 
Therefore, nociception can be regulated at different levels of the nervous system through 
facilitating (pronociceptive) or inhibitory (antinociceptive) actions. Particularly, the dorsal 
horn of the spinal cord stands as a critical site for nociceptive modulation, receiving both 
information about painful stimuli from the periphery as well as descending feedback from 
supraspinal centers, which ultimately regulates (with inhibition or further facilitation) the 
output from the spinal cord [31]. 
Steroids play pivotal physiological roles in the nervous system, including the modulation of 
pain sensitivity [8,37,38]. Steroids are able to exert their effects by binding to 
intracellular/nuclear receptors thus influencing gene transcription and signaling pathways 
[39,40], or by rapidly modulating membrane excitability and synaptic transmission through 
their interaction with ionotropic neurotransmitter receptors, such as γ-aminobutyric acid 
type A (GABAA) and N-methyl-D-aspartate (NMDA) receptors, or voltage-dependent Ca2+ 
or K+ channels [39-41]. Moreover, several steroids can also influence second-messenger 
pathways by directly interacting with specific membrane receptors [40,42]. 
Specifically, the spinal cord is not only a target for circulating steroids, but also an active 
steroid-producing site, that contains an array of regulatory proteins and enzymes involved 
in neurosteroid production and metabolism [37,38]. Accordingly, the impact of circulating 
steroids and neurosteroids on nociceptive processing at the spinal level has been largely 
studied, mainly in the context of stress response [9,43], pregnancy [44-46], estrous cycle 
[47,48] and sex-dimorphic responses to both noxious stimuli and opioid administration [49-
51].  
The impact of the stress response on nociception is multifaceted, and involves a large 
number of neurotransmitters and neuropeptides [52]. Acute stress is most commonly 
associated with the induction of analgesia, whereas chronic stress has been more 
frequently linked with the onset of hyperalgesia [52]. In this context, changes in circulating 
levels of glucocorticoids, occurring as part of the stress response, may impact on 
nociceptive processing at spinal level [43,53].  
One recent study has shown that high levels of plasma corticosterone produce analgesia, 
by its convertion into its neuroactive 3α,5α-reduced metabolite in the spinal cord, which 
enhances GABAergic spinal inhibitory transmission and decreases nociceptive inputs [43]. 
Further, chronic glucocorticoid administration can also modulate the spinal expression of 
neuropeptides i.e. substance P (SP) and calcitonin gene-related peptide (CGRP), involved 
in nociceptive transmission [54], confirming that these steroids regulate physiological pain 
processing at the dorsal horn level. 
Less is known about the participation of aldosterone in nociceptive modulation. Various 
preclinical and clinical studies have documented the role of the renin–angiotensin–
aldosterone system in pain processing [55] and the consequences of experimental 
activation of the mineralocorticoid receptor, which increases the severity of inflammation 
[56], a key component in pain generation. However, the participation of the 
mineralocorticoid receptor in nociception and pain conditions deserves further 
investigation. 
  
 
Regarding the role of ovarian steroids, data arising from experimental models of 
pregnancy [44-46] found that, in late pregnancy, progesterone and estradiol recruit spinal 
anti-nociceptive systems involving dynorphin and both kappa and delta opioid receptors 
(KOR and DOR, respectively), a process associated with significant elevations in 
nociceptive response thresholds [57]. In particular, progesterone is crucial in mediating 
maternal antinociception and contributing to sex-based differences in pain sensation [49]. 
In fact, sexual dimorphism in nociception has been extensively documented in human and 
experimental animals [50,51,58]. Although several factors are involved in these complex 
differences, the fact that estrogens and progesterone have a multitude of effects on opioid 
systems [59-61], strongly point to these steroids as foremost determinants of sex-
dependent nociception and sex-dimorphic opioid antinociception. 
The spinal cord has been shown to be a central nervous system region in which the 
regulation of opioid antinociception displays a clear sexual dimorphism. In experimental 
conditions, the conformation of spinal mu- and kappa-opioid receptor (MOR/KOR) 
heterodimers, which results antinociceptive, is strikingly sexually dimorphic, being higher in 
spinal cord of females vs. males and also varying between stages of the estrus cycle, 
which suggests its regulation by estrogens and/or progesterone [60]. Further, 
endomorphin 2, the predominant endogenous MOR ligand in the spinal cord, not only 
mediates analgesia depending on the stage of the estrus cycle but also exhibits a sexual 
dimorphism in the mechanisms utilized to elicit antinociception [61-63]. Fluctuations in 
estrogen and progesterone in different phases of the menstrual cycle also affect pain 
perception [64] and the nociceptive thresholds differ across the estrous cycle of the rat as 
well [47,48,65]. However, inconsistent and paradoxical effects have been described, 
showing that these hormones generate both antinociceptive and pronociceptive actions 
[51,66]. Thus, the accurate role of these hormones and the underlying mechanisms 
mediating these events remain elusive and under permanent investigation [for a recent 
review see [67]]. 
In addition to these controversial results, the role of androgens in pain perception cannot 
be ignored [50,68]. In both sexes, androgens are primarily synthesized in the gonads but 
also by the reticular portion of the adrenal gland as dehydroepiandrosterone (DHEA). In 
addition, DHEA synthesis also occurs in neural networks of the spinal cord dorsal horn 
[37,69]. DHEA, its sulfate derivative (DHEAS) and testosterone, one of the major 
androgens deriving from DHEA, have been shown to impact spinal nociceptive 
transmission [69,70]. DHEA acute treatment induces a rapid pronociceptive and a delayed 
antinociceptive action in naive animals and also in pain conditions, whereas spinal 
intrathecal administration of testosterone induces a significant analgesic effect by 
increasing the nociceptive thresholds [69]. The biphasic effect observed after DHEA 
treatment suggests that DHEA itself is capable of decreasing both thermal and mechanical 
thresholds, while its androgenic metabolites may exert analgesic actions [69]. Recently, 
the individual differences in testosterone levels revealed that this steroid may also be 
related to antinociception and protective effects against noxious stimuli in healthy women 
[71]. 
  
 
In males, testosterone is also converted into its 5α-reduced metabolites 
dihydrotestosterone (DHT) and 5α-androstane-3α,17β-diol (3α-diol). These two 
testosterone metabolites have been reported to induce analgesia, in gonadectomized rats, 
when evaluated using the tail flick and the paw lick tests [72], as well as during different 
pain conditions [37,69]. Moreover, testosterone can be converted to estradiol by the 
enzyme aromatase, implying that the specific effects of testosterone are complex to be 
evaluated. Aromatization of testosterone into estrogen reduces the response to a noxious 
stimulus in the male quail [73,74] mediated at the spinal cord level by the interaction of 
estradiol with estrogen receptors and/or by fast nongenomic actions [74]. 
 
The use of positive allosteric modulators of inhibitory amino acid receptor channels, such 
as GABAA receptors, appears to be particularly important in pain modulation. Specifically, 
GABAA receptors located in spinal neurons represent an interesting target to limit pain 
expression. Endogenous progesterone-derived neurosteroids and synthetic analogs of 
3α,5α-reduced derivatives of progesterone, acting as potent allosteric modulators of 
GABAA receptors and/or T-type calcium channels, are particularly efficient to elevate 
nociceptive thresholds in naive animals [13-15,75,76]. In addition, neurosteroids can also 
modulate GABAA receptor subunit expression and reorganization [77]. 
 
Altogether, these findings point to the crucial actions of neurosteroids /neuroactive steroids 
on spinal nociceptive networks, and propose their use as agents able to modulate pain 
messages. 
3. Neuropathic pain: definition, etiology and mechanisms 
From an evolutionary point of view, nociceptive pain can be considered as a necessary 
evil since it provides a potent warning system that protects an individual from either actual 
or potential tissue damage [31]. However, not every type of pain is part of this adaptive 
response. Neuropathic pain, is a chronic pain that may arise after an injury or disease 
affecting the somatosensory system [78] and is considered a maladaptive response of the 
nervous system to damage [79,80].  
Neuropathic pain classical etiologies include diabetic polyneuropathies, postherpetic 
neuralgia, trigeminal neuralgia, painful radiculopathies, central post-stroke pain and spinal 
cord injury pain, although traumatic, postsurgical and chemotherapy-associated 
neuropathies also represent common conditions [81,82]. Due to this diversity, neuropathic 
pain afflicts as much as 7-10% of the general population, worldwide. Despite the fact that 
diseases causing neuropathic pain vary substantially, patients present common clinical 
characteristics, with the presence of both negative and positive symptoms which 
respectively represent loss and gain of function of the somatosensory pathway. Negative 
phenomena arise as sensory loss, while positive phenomena include both ongoing (also 
called spontaneous) and evoked pain [81]. Two prominent neuropathic pain-associated 
symptoms are allodynia, pain induced by normally innocuous stimuli, and hyperalgesia, 
increased pain response elicited by noxious stimuli [81]. Pain with neuropathic 
characteristics is severe and constitutes a very important physical and psychological 
  
 
burden. Furthermore, chronic pain generates an elevated and sustained economical cost 
for the individuals, their families and their communities [83]. In fact, pain represents the 
greatest economic burden of any pathological condition in the USA, with an estimated 
annual cost of $600 billion. Unfortunately, the treatment of neuropathic pain is still 
unsatisfactory, with a substantial number of patients having decreased quality of life with 
little or no benefit from available treatments [84]. 
 
It is now clear that injury or disease of the somatosensory system results in maladaptive 
plasticity that profoundly alters signaling at different levels along the pain pathway, from 
the peripheral nerves to the cortex [32]. Maladaptive changes can affect either the 
peripheral or the central nervous system and lead to increased excitability of the neuronal 
pain processing circuitry, generating peripheral or central sensitization, which are 
symptomatically expressed as allodynia and hyperalgesia [31]. This plasticity involves 
multiple and diverse mechanisms such as: a) the ectopic activity of primary afferents, 
mainly related to altered trafficking of receptor ion channels; b) changes in the phenotype 
of sensory neurons, affecting different molecules and in particular neuropeptides such as 
SP and CGRP; c) the imbalance of excitatory and inhibitory neurotransmission at the 
dorsal horn level, mainly involving increased NMDA receptor-mediated currents and 
decreased GABAA receptor activity; d) an exacerbated neuroimmune reaction, with glia 
activation and the production of pro-inflammatory mediators; and e) increased descending 
facilitation from the brainstem and supraspinal centers [32,79,80,85]. As a consequence of 
these different and often coexisting pathophysiological mechanisms, this type of pain 
commonly results refractory to conventional treatments [84]. 
 
4. Progesterone and allopregnanolone in neuropathic pain conditions 
It has recently become clear that the treatment of neuropathic pain needs to move from 
merely suppressing symptoms to a disease-modifying strategy aimed at preventing the 
different events leading to maladaptive plasticity, described in the previous section. As 
extensively demonstrated, steroids control several aspects of the development, activity 
and plasticity of the nervous system [6,8,12] and thus appear as interesting candidates for 
these purposes. 
Among steroidal compounds, synthetic glucocorticoids (i.e. dexamethasone, 
methylprednisolone) have been effectively used to reduce certain kinds of pain when given 
in large systemic doses, mainly through the inhibition of pro-inflammatory cytokines or the 
upregulation of lipocortin (annexin-1), an anti-inflammatory molecule that blocks the 
production of eicosanoids [86].  However,  corticosteroids exert paradoxical effects during 
chronic pain [9,87] and may exacerbate neuropathic pain conditions [88-90].  
Glucocorticoid receptors are up-regulated in the spinal dorsal horn during experimental 
neuropathic conditions and contribute to hyperalgesia [91]. Moreover, stress exacerbates 
neuropathic pain via glucocorticoid and NMDA receptor activation [90] and spinal 
glucocorticoid receptors have been shown to mediate morphine tolerance, a 
pharmacological phenomenon that hampers the clinical use of opioids [92]. These data 
  
 
raise concern since glucocorticoid-mediated anti-inflammatory therapies, which are often 
used after nervous system injury, may produce maladaptive plasticity contributing to the 
onset and maintenance of neuropathic pain [88,89]. 
It is now a well-consolidated concept that a certain group of steroids, such as 
progesterone and its reduced derivatives, 5α-dihydroprogesterone (DHP) and 3α,5α-
tetrahydroprogesterone (THP), also known as allopregnanolone (ALLO), are 
neuroprotective agents in the central and peripheral nervous system [6,8,12,93]. 
Progesterone is synthesized by ovaries and placenta in females, and by adrenal glands in 
both males and females. Progesterone is also locally synthesized by the nervous system 
which has the capacity to convert progesterone into its neuroactive metabolite ALLO as 
well. These molecules have been shown to exert beneficial and neuroprotective effects in 
experimental models of Alzheimer´s disease, Parkinson´s disease, multiple sclerosis and 
traumatic brain and spinal cord injury [6,94-97]. Recently, it has been found that these 
steroids also reduce pain-related behaviors in several neuropathic pain models (i.e 
peripheral nerve injury, diabetes, spinal cord injury) [17-23,29,30] (Table 1).  
In the peripheral nervous system, progesterone and its metabolites are able to restore 
biochemical, morphological and functional parameters after physical injury of peripheral 
nerves [98,99]. In animals subjected to a sciatic nerve crush, progesterone and/or DHP 
administration counteracts the injury-induced decrease in the expression of myelin 
proteins such as myelin protein zero (P0), peripheral myelin protein 22 (PMP22) and 
myelin and lymphocyte protein (MAL), as well as the injury-induced increase in the activity 
of Na+K+ ATPase pump [98]. In addition, the steroids are able to restore the impairments in 
nociceptive thresholds detected in vehicle treated injured animals.  
Using an animal model of diabetic neuropathy, Leonelli and colleagues showed that 
progesterone, DHP and ALLO improve sciatic nerve conduction velocity, thermal 
nociceptive threshold, skin innervation density, P0 and PMP22 expression levels and 
Na+K+ ATPase activity [100]. Furthermore, Afrazi and colleagues recently reported that 
chronic treatment with ALLO prevents the diabetes-induced spinal down-regulation of γ2 
subunit of GABAA receptor and counteracts thermal hyperalgesia, as well as motor 
impairment [29]. 
In addition, our laboratory has recently shown that progesterone treatment prevents 
mechanical allodynia and significantly reduces the number of painful responses to cold 
stimulation in male animals subjected to a sciatic nerve chronic constriction injury [18]. In 
correlation with the observed attenuation of pain behaviors, progesterone administration 
prevents the injury-induced increase in the expression of the NR1 subunit of NMDA 
receptor and the gamma isoform of the enzyme protein kinase C (PKCγ), both key players 
for chronic pain generation [18]. A report from Dableh and colleagues further supported 
progesterone antiallodynic effects after peripheral nerve injury, showing that the steroid 
prevents neuropathic pain-associated behaviors only if the treatment is started early and 
maintained for a critical period of time [20]. Interestingly, after nerve root ligation 
progesterone-dependent regulation of the growth factor neuregulin-1 in the spinal cord of 
  
 
female rats was shown to mediate sex differences in the maintenance phase of central 
sensitization [101]. Therefore, additional research designed to elucidate the mechanisms 
driving sex differences after progesterone administration in pain conditions is needed. 
 
ALLO has also been shown to reduce mechanical and thermal hyperalgesia after sciatic 
nerve ligature [21], probably through its blockage of neuronal low-voltage activated (T-
type) Ca2+ channels and the potentiation of GABAA ligand-gated channels.  
 
Furthermore, progesterone and its derivatives DHP and ALLO suppress neuropathic 
symptoms evoked by antineoplastic drugs, such as vincristine [22] or oxaliplatin [23] in 
animal models of chemotherapy-induced painful neuropathy. The cited neurosteroids both 
prevent and revert mechanical allodynia and hyperalgesia, when they are administered 
either before or after the establishment of pain behaviors. Steroid treatment also 
counteracts vincristine-induced decrease in the number of intra- epidermal nerve fibers 
and nerve conduction velocity [22]. 
Early progesterone administration also prevents mechanical and thermal allodynia after 
spinal cord injury [17,19]. Notably, these anti-allodynic effects are maintained even after 
the treatment has stopped, supporting the relevance of targeting the key components of 
the central injury cascade occurring early after a spinal cord lesion [17]. In this regard, we 
have shown that progesterone administration is able to attenuate the injury-induced 
increase in the number of immunoreactive astrocytes and microglial cells and in the 
expression of pro-inflammatory mediators: enzymes, such as the inducible isoform of nitric 
oxide synthase (iNOS) and cyclooxygenase 2 (COX-2), and cytokines, such as the 
interleukins (IL) IL-1β, IL-6 and tumor necrosis factor α (TNFα), probably by decreasing 
the transactivation potential of the transcription factor NFκB [17,30]. In addition, animals 
receiving progesterone show lower levels of expression of NR1, NR2A and NR2B subunits 
of the NMDA receptor, a key player in the process of central sensitization, when compared 
with vehicle-treated animals [19]. Progesterone administration also results in lower 
expression of PKCγ, increased KOR mRNA levels and reduced number of neuronal 
profiles exhibiting immunoreactivity for the phosphorylated (activated) form of NR1 (pNR1) 
in the chronic phase after injury [19]. NR1 phosphorylation, a post-translational 
modification that is essential to enhance NMDA receptor activity, results in increased 
neuronal responsiveness and pain [102]. Thus the steroid, by preventing the maladaptive 
changes in the expression and/or activity of several pain related molecules is able to 
prevent allodynia after spinal cord injury.  
Overall, the molecular changes taking place after progesterone, DHP or ALLO 
administration to different animal models of neuropathic pain suggest that, by preventing 
maladaptive plasticity, these steroids could be favoring a molecular scenario that prevents 
the onset of neuropathic pain. As shown here, steroids stand as excellent candidates since 
they are able to block multiple cellular and molecular events leading to damage at the 
different control levels. Therefore, these steroids might provide a valuable tool for 
alleviating chronic pain in the clinical setting. 
  
 
Progesterone in particular has several features that make it an attractive potential drug for 
the treatment of injuries or diseases of the nervous system leading to chronic pain. Due to 
the wide experience derived from its administration in hormone replacement therapy, its 
pharmacokinetic and pharmacodynamic properties are well known. In addition, 
progesterone can be administered systemically since it is able to cross the blood-
brain/spinal barrier; it is widely available and has low cost and limited adverse effects. In 
fact, progesterone administration has already been shown to be safe and well tolerated in 
patients with traumatic brain injury [103,104]. In relation to ALLO, data showing safety and 
tolerability in patients is still needed. In fact, a phase II clinical trial designed to test safety 
and effectiveness of ALLO in patients with traumatic brain injury is now recruiting patients 
(https://clinicaltrials.gov/ct2/show/NCT01673828%3Fterm=traumatic+brain+injury+and+all
opregnanolone&amp;rank=1). 
In addition, the effects of a single, local administration of 17-α-hydroxyprogesterone 
caproate have been evaluated in patients with mild carpal tunnel syndrome, and compared 
with those observed after local treatment with corticosteroid [105]. Patients receiving the 
long-acting synthetic progesterone derivative showed a reduction in pain scores, similar to 
that observed after corticosteroid treatment, one month after injection, whereas only 
patients receiving 17-α-hydroxyprogesterone caproate still manifested symptoms of relief 
six months after treatment [105].  
5. Potential mechanisms underlying progesterone and allopregnanolone actions 
towards pain control  
As shown in the previous section, after a lesion or disease of the nervous system both 
progesterone and ALLO exert concerted beneficial influences on multiple processes, 
avoiding maladaptive changes and pain behaviors. Those pleiotropic effects are mediated 
via regulation of gene transcription, intracellular signaling pathways and neurotransmission  
[40]. 
In the spinal cord, an array of progesterone receptors are expressed in both neurons and 
glial cells [40,42]. These include: a) the classic nuclear receptor (PR) [106], that may be 
targeted to the nucleus and act as a ligand-activated transcription factor regulating the 
expression of target genes or may be delivered to the cell membrane where it interacts 
with Src/Ras/MAPK signaling pathway; b) progesterone membrane receptors (mPR) [107], 
which contain seven integral transmembrane domains and mediate signaling via an 
inhibitory G-protein coupled pathway and stimulate MAPK pathway; and c) the membrane-
associated protein progesterone receptor-membrane component 1 (PGRMC1) [108], a 
progesterone binding site that has several potential signaling mechanisms, including 
Jak/STAT and Src pathways and the activation of protein kinase G (Fig 2). Thus, similarly 
to what has been observed in other nervous system structures, the spinal cord offers 
multiple sites for progesterone actions [8,40,42].  
In addition, progesterone also inhibits the activity of the nicotinic acetylcoline receptor 
[109] and acts as an competitive antagonist of sigma-1 receptor biding site [110]. The 
activation of sigma-1 receptor, which is strongly expressed in the dorsal spinal cord [111] 
  
 
and associated with central sensitization and pain [112], enhances NMDA receptor 
mediated currents via PKC-dependent phosphorylation of the NR1 subunit [113]. 
Therefore, progesterone, acting as competitive antagonist of sigma-1 [110,114], could be 
reducing pain behavior through this mechanism, among others. 
As mentioned, gene expression regulation may be mediated through progesterone or DHP 
binding to the intracellular classical receptors PR-A and PR-B [40,42]. Thus, target genes 
exhibiting progesterone response elements in their promoters allow a direct control of their 
expression by PR. However, it still remains unclear whether these response elements are 
present in the promoters of the molecules previously mentioned to be modulated by 
progesterone in different animal models of pain. Nevertheless, since PR can cross-talk 
with members of the AP-1, NFκB and Sp families of transcription factors or interact with 
the Src/Ras/MAPK and the cAMP signaling pathways [40], regulation of target genes could 
be achieved even in the absence of steroid-response elements. In fact, progesterone 
regulation of pro-inflammatory cytokines and enzymes could be mediated through PR 
modulation of NFκB transactivation potential [17,115]. The steroid is a well-known 
regulator of NFκB activity [116], through its ability to antagonize NFκB by either a direct 
PR-mediated interaction with the transcription factor [117], or by the modulation of the 
expression and activity of NFκB and its inhibitory protein IκBα [118]. Since NFκB regulates 
glia activation and the production of a wide array of pro-inflammatory mediators, these 
mechanisms could explain progesterone anti-inflammatory actions in different animal 
models of pain [17]. 
In contrast to progesterone and DHP, ALLO does not bind to PR and acts by modulating 
neurotransmitter receptors. In fact, at least part of progesterone´s anti-allodynic and 
anxiolytic effects could be due to its rapid conversion to ALLO [119], metabolite that 
reinforces inhibitory neurotransmission by acting as a positive allosteric modulator of 
GABAA receptor [120] and by enhancing specific GABAA receptor subunits [121]. In fact, 
ALLO is one of the most potent endogenous positive allosteric modulators of GABAA 
receptor function. 
To further complicate this scenario, the pregnane xenobiotic receptor (PXR) has been 
shown to act not only as a novel target of ALLO in the brain, for functional, reproductively-
relevant responses, but also in the biosynthesis of ALLO (i.e., acting upstream of TSPO, 
translocator protein involved in the first step of steroidogenesis) [122]. However, whether 
these mechanisms are involved in experimental neuropathic conditions remains to be 
explored. 
Since progesterone and ALLO appear as novel and promising molecules in pain 
modulation, with several neuroprotective properties and exerting anti-allodynic and anti-
hyperalgesic actions, further studies contributing to unravel their mechanisms of action in 
painful conditions should be carried out. 
 
 
  
 
6. Spinal cord neurosteroidogenesis  
It is now well-established that steroids can be synthesized both in the peripheral and the 
central nervous system either de novo from cholesterol or from circulating steroid 
hormones, that easily cross the blood-brain / spinal barrier and serve as precursors for 
neurosteroidogenic enzymes. Both neurons and glial cells (astrocytes, oligodendrocytes, 
Schwann cells and ganglia satellite cells) participate in neuroactive steroid biosynthesis 
and metabolism [12,37,123-126]. Neurosteroids include a broad group of molecules 
(androgens, estrogens, progestagens and their derivatives); in this section we will focus on 
the enzymatic pathways leading to the synthesis of progesterone and ALLO at the spinal 
cord level.  
In the spinal cord, the presence and the biological activity of several key steroidogenic 
enzymes have been demonstrated [12,37,38,119,127-129]. As well as in other 
steroidogenic tissues, biosynthesis of steroid hormones in the spinal cord begins with the 
translocation of cholesterol from intracellular stores to the inner mitochondrial membrane. 
This transport, considered the rate limiting step for neurosteroidogenesis, is hormonally 
controlled and mediated by the steroidogenic acute regulatory protein (StAR/STARD1) 
[130-132] and the 18kDa translocator protein (TSPO), previously known as peripheral 
benzodiacepine receptor [133] (Fig 3). Cholesterol is then converted into pregnenolone 
(PREG), in a reaction catalyzed by the enzyme P450 side-chain cleavage (P450scc) 
located on the matrix side of the inner mitochondrial membrane. The enzyme 3β-
hydroxysteroid dehydrogenase (3β-HSD) converts pregnenolone into progesterone, which 
is further reduced into 5α-DHP by the action of 5α-reductase (5α-R). Finally, 3α-
hydroxysteroid oxidoreductase (3α-HSOR) is responsible for the reduction of DHP into 
ALLO (3α,5α-THP) [12,37,93]. 
Notably, several neurosteroids, in particular pregnenolone and progesterone are 
measurable in the rat spinal cord even in adrenalectomized and gonadectomized animals, 
further supporting their local biosynthesis [119].  
 
7. Promoting neurosteroidogenesis as a therapeutic strategy 
The local production of neurosteroids during several pain conditions has been extensively 
studied in the spinal cord [37,69,134,135], dorsal root ganglia [125,126,136] and peripheral 
nerves [98,100,137]. As previously mentioned, we will make special focus on the spinal 
cord dorsal horn, an active steroid-producing center that contains various key 
steroidogenic enzymes and where local steroid secretion is regulated in different chronic 
pain conditions [37,38].  
In the spinal cord of animals subjected to a sciatic nerve ligature, there is a threefold 
increase in the mRNA levels of the enzyme P450scc [138], and this up-regulation 
correlates with a significant increase in the density of P450scc-positive fibers in the 
ipsilateral dorsal horn of neuropathic animals [127]. By using reversed-phase HPLC 
analysis coupled with flow scintillation detection to evaluate the conversion of 
  
 
[3H]cholesterol into [3H]PREG by tissue homogenates from the lumbar dorsal horn, Patte-
Mensah and colleagues showed that the newly synthesized [3H]PREG is 80% higher in the 
spinal cord of neuropathic animals [127,138]. In addition, there is an increase in the 
endogenous concentrations of PREG and ALLO in the dorsal horn of animals with 
neuropathic pain provoked by peripheral nerve injury, while their plasma levels do not 
change [138]. In correlation with these findings, the mRNA levels and biological activity of 
3α-HSOR, the enzyme involved in the biosynthesis of ALLO also increase in the spinal 
cord of animals subjected to a chronic constriction injury, and contribute to reduce thermal 
hyperalgesia and mechanical allodynia [27]. In the spinal cord of streptozotocin-induced 
diabetic rats the gene encoding for 3β-HSD shows a ninefold increase and the amount of 
[3H]progesterone newly synthesized is 200% higher than in control animals [139]. 
Thus, in different painful states, there is an up-regulation of the biosynthetic pathways 
leading to progesterone and ALLO production, probably as an endogenous mechanism 
triggered to cope with the chronic pain condition [37,38]. In line with this concept, the local 
production of DHEA, a steroid with pro-nociceptive actions, is reduced in the spinal cord of 
neuropathic animals, due to the down-regulation of the enzyme involved in its biosynthesis 
[69]. Thus, during neuropathic pain conditions, neurosteroid biosynthesis appears to be 
selectively regulated in the spinal cord sensory networks, tending to increase the local 
production of antinociceptive steroids such as progesterone and ALLO, and to reduce the 
formation of pronociceptive neurosteroids such as DHEA. 
Based on these findings, an attractive area of research has recently been dedicated to 
promote endogenous neurosteroidogenesis in the nervous system, as a potential 
therapeutic strategy with the intrinsic advantage of limiting the typical endocrine side 
effects of long-term systemic administered steroids [11,140]. In fact, the induction of 
neuroactive steroids synthesis has been recently evaluated both in the peripheral and 
central nervous sytems [25,26,141-144].  
The production of neurosteroids may be controlled by the endogenous activation of the 
translocator protein of 18 kDa (TSPO), localized predominantly in the outer mitochondrial 
membrane, and involved in the first step of neurosteroidogenesis by stimulating the 
translocation of cholesterol across the inner mitochondrial membrane [145]. With this 
perspective, the administration of TSPO ligands, such as Ro5-4864 or etifoxine, has been 
used as promising options to control pain conditions [26,143,144] (Table 2). In fact, the 
use of TSPO ligands increases the levels of endogenous PREG and progesterone in the 
sciatic nerve of diabetic animals, counteracting the impairments in thermal thresholds and 
nerve conduction velocity arising during diabetic neuropathy [142], reduces astrocyte 
activation and decreases established mechanical allodynia and thermal hyperalgesia after 
spinal nerve ligation [26] and exerts beneficial effects modulating vincristine-induced 
neuropathic pain [143].  
Indeed, additional pharmacological strategies aimed to stimulate the local production of 
neurosteroids are now being developed [25,140,141]. The activation of the nuclear liver X 
receptors (LXRs) with the synthetic ligand GW3965, results in increased levels of the 
  
 
neuroactive steroids PREG, progesterone, DHP and/or ALLO in the sciatic nerve, the 
spinal cord, cerebellum and cerebral cortex of diabetic rats, in association with 
neuroprotective effects on thermal nociceptive activity, nerve conduction velocity, Na,K-
ATPase activity and the expression of myelin proteins both in peripheral nerves and the 
spinal cord [25,141].  
LXRs are ligand activating transcription factors that belong to the nuclear receptor 
superfamily and serve as cholesterol sensors, preventing its excessive intracellular 
accumulation, by their ability to regulate the transcription of genes involved in cholesterol 
homeostasis. LXRs have been shown to regulate StAR expression in the adrenal glands, 
thus modulating the rate of steroidogenesis [146]. In agreement with those findings, 
GW3965 restores StAR mRNA levels in the sciatic nerve of diabetic animals, and 
increases the local levels of neuroactive steroids [25]. Interestingly, LXR activation does 
not affect plasma levels of the cited neurosteroids [25], thus avoiding possible systemic 
side effects which results advantageous in relation to TSPO ligands, that have been 
shown to increase both local and plasma neurosteroid levels in experimental diabetic 
neuropathy [142]. It is interesting to note that both pharmacological approaches are able to 
increase the local levels of neurosteroids, only in pathological situations when these levels 
are affected [141]. Therefore, the potential neuroprotective and pain-reducing activities of 
both TSPO and LXR ligands in other experimental models of neuropathic pain merit to be 
systematically explored. 
Major future challenges for steroid-based therapy and/or steroidogenic-promoting 
strategies are related to the selection of the doses and treatment regimens that show the 
best benefit/risk ratio, in order to optimize favorable actions and reduce adverse side 
effects [12]. Sex-specific treatments and the type of injuries and/or the etiology of the 
diseases feasible of receiving steroid therapies should also be determined. In addition, 
different administration routes, feasible and practical in clinical settings, as well as physico-
chemical properties for adequate formulation and delivery should also be evaluated [12]. 
8. Concluding remarks 
-In spite of the increasing knowledge on pain mechanisms, the identification of appropriate 
targets for the prevention and /or treatment of neuropathic pain remains a major challenge. 
-Exogenously administered progesterone and/or ALLO, or the stimulation of their local 
production in the nervous system may represent an attractive option to prevent or treat 
pain after peripheral or central nervous injuries. 
-Major challenges for steroid-based therapy, including the evaluation of pharmacokinetics, 
bioavailability, safety and sex-differences in the levels or in the action of neuroactive 
steroids, should be faced for a successful translational approach in severe neuropathic 
pain conditions. 
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Figure legends 
Figure 1: Schematic representation of the pain pathway 
Noxious stimuli are detected by nociceptors, a subpopulation of primary afferent neurons. 
They are located in dorsal root ganglia and have a peripheral axonal branch that 
innervates tissues and organs, and a central branch that synapse on second order 
neurons within the dorsal horn of the spinal cord, which convey nociceptive information to 
the brain. 
Figure 2: Multiple receptors involved in progesterone and allopregnanolone actions 
Progesterone pleiotropic effects are mediated via interaction with an array of progesterone 
receptors including the classic nuclear receptor (PR), progesterone membrane receptors 
(mPR) and the membrane-associated protein progesterone receptor-membrane 
component 1 (PGRMC1). In addition, progesterone acts as a competitive antagonist of 
sigma-1 receptor.  
Allopregnanolone does not bind to PR and acts by modulating neurotransmitter receptors. 
In fact, allopregnanolone is one of the most potent endogenous positive allosteric 
modulators of GABAA receptor, thus reinforcing inhibitory neurotransmission  
Figure 3: Biosynthetic pathway of progesterone and allopregnanolone  
Cholesterol is translocated into the inner mitochondrial membrane by the 18kDa 
translocator protein (TSPO) and the steroidogenic acute regulatory protein, and is then 
converted into pregnenolone by the enzyme P450 side-chain cleavage (P450scc). The 
conversion of pregnenolone into progesterone is catalized by the enzyme 3β-
hydroxysteroid dehydrogenase (3β-HSD). By the action of 5α-reductase (5α-R), 
progesterone is then reduced into 5α-dihydroprogesterone, which is further reduced into 
3α,5α-tetrahydroprogesterone, also known as allopregnanolone, by 3α-hydroxysteroid 
oxidoreductase (3α-HSOR).  
 
Table 1: Effects of exogenously administered neuroactive steroids on different 
experimental models of neuropathic pain 
 
Table 2: Steroidogenic-promoting strategies used in animal models of neuropathic 
pain 
  
  
  
Figure 2
  
Figure 3
  
Neuroactive  
steroid 
Experimental 
 model 
Effects on nociception /  
pain behaviors 
Targets Citation 
PG Spinal cord injury Prevents paw mechanical  
and thermal allodynia 
Prevents the injury- induced increase in spinal 
NMDA receptor subunits and PKC mRNA levels. 
Attenuates the injury-induced increase in the 
number of immunoreactive astrocytes and 
microglial cells, and in COX-2 and iNOS mRNA 
levels in the spinal cord. 
Prevents IL1, TNF, IL-6 and IL1-RI spinal up-
regulation. Results in lower number of dorsal horn 
neurons expressing IL1-RI. 
Coronel et 
al., 2011 
Coronel et 
al., 2014 
 
 
Coronel et 
al., 2016 
PG Sciatic nerve  
constriction by 
single ligature 
Prevents paw mechanical  
and thermal allodynia 
Results in lower number of dorsal horn neurons 
expressing NR1, pNR1 and PKC. 
Coronel et a., 
2011 
PG Sciatic nerve  
constriction by 
cuffing 
Prevents paw mechanical 
allodynia 
 Dableh et al., 
2011 
PG Trigeminal nerve 
root demyelination 
Prevents orofacial 
mechanical allodynia 
Recovers P0 and PMP22 expression. Kim et al., 
2012 
PG/DHP Sciatic nerve crush Counteracts paw 
nociception impairment 
after thermal stimulation 
Counteracts injury-induced decrease in the 
expression of myelin proteins P0, PMP22, MAL. 
Improves Na+,K+ATPase pump activity and 
reduces the injury-induced increase in myelinated 
fibers density. 
Roglio et al., 
2008 
PG/DHP 
/ALLO 
Streptozotocin- 
induced  
diabetic 
neuropathy 
Counteracts paw 
nociception impairment 
after thermal stimulation 
Restores skin innervation density, improves 
Na
+
,K
+
ATPase pump activity and reduces the 
injury-induced decrease in the expression of 
myelin proteins P0 and PMP22. Counteracts the 
impairment in nerve conduction velocity.  
Leonelli et 
al., 2007 
PG/DHP 
/ALLO 
Vincristin-induced 
peripheral 
neuropathy 
Prevents and eradicates 
paw mechanical 
allodynia and 
hyperalgesia 
Counteracts vincristine-induced alterations in 
peripheral nerves including 2,3cyclic nucleotide 3-
phosphodiesterase, neurofilament 200 kDa and 
intraepidermal nerve fiber repression. Restores 
nerve conduction velocity. 
Meyer et al., 
2010 
ALLO Sciatic nerve 
ligation 
Alleviates paw 
mechanical and thermal 
hyperalgesia 
 Pathirathna 
et al., 2005 
ALLO Streptozotocin- 
induced  
diabetic 
neuropathy 
Ameliorates paw  
thermal hyperalgesia 
Prevents diabetes-induced GABAA receptor down-
regulation. 
Afrazi et al., 
2014 
ALLO Oxaliplatin-induced 
peripheral 
neuropathy 
Prevents and abolishes 
paw mechanical 
allodynia, mechanical 
hyperalgesia and thermal 
allodynia 
Restores neurofilament 200 kDa expression,  
intraepidermal nerve fiber density and nerve 
conduction velocity. 
Meyer et al., 
2011 
 
Table 1
  
Ligands Experimental 
 model 
Effects on nociception /  
pain behaviors 
Targets Citation 
TSPO ligand 
(Ro5-4864) 
Streptozotocin- 
induced  
diabetic neuropathy 
Counteracts paw 
nociception impairment 
after thermal 
stimulation 
Increases the levels of PREG and PG in the sciatic 
nerve. Counteracts the impairment in nerve 
conduction velocity. Restored skin innervation 
density and P0 mRNA levels, and improves Na
+
,K
+
-
ATPase activity.  
Increases the levels of PREG, PG, DHP and ALLO in 
the spinal cord. 
Giatti et al., 
2009 
 
 
 
Mitro et al., 
2012 
TSPO ligand 
(Ro5-4864) 
L5 spinal nerve  
ligation 
Reverts paw mechanical 
allodynia and thermal 
hyperalgesia 
Inhibits activated astrocytes and reduces TNF 
expression. 
Wei et al., 
2013 
TSPO ligand 
(etifoxine) 
Vincristin-induced 
peripheral 
neuropathy 
Prevents and abolishes 
paw mechanical 
hyperalgesia and 
thermal allodynia 
Increases the levels of 3-reduced neuroactive 
steroids such as ALLO 
Aouad et al., 
2009 
LXR ligand 
(GW3965) 
Streptozotocin- 
induced  
diabetic neuropathy 
 Increases the levels of DHP and ALLO in the spinal 
cord. Restores MBP expression. 
Mitro et al., 
2012 
LXR ligand 
(GW3965) 
Streptozotocin- 
induced  
diabetic neuropathy 
Counteracts paw 
nociception impairment 
after thermal 
stimulation 
Increases the expression of P450scc, StAR and 5-
reductase, and the levels of PREG, PG and DHP in 
the sciatic nerve. Counteracts the impairment in 
nerve conduction velocity and Na
+
,K
+
-ATPase 
activity. 
Cermenati 
et al., 2010 
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Highlights 
 
 
• Neuroactive steroids are involved in the modulation of pain sensitivity 
• Neuroactive steroids also modulate pain messages in neuropathic conditions 
• Progesterone and Allopregnanolone administration might counteract chronic pain  
• Neurosteroids locally produced in the spinal cord also reduce neuropathic pain  
• Promoting neurosteroidogenesis represent a useful tool to alleviate neuropathic pain 
 
 
